Aprea Therapeutics, Inc.
APRE
$-0.10
Change (1 day)
$8.85
Year High
$2.15
Year Low
Categories
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
Aprea Therapeutics, Inc. (APRE) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | -21,606,820 | 4.39 M | 22.65 M | 22.52 M | |
| 2022 | -28,786,647 | 4.51 M | 30.16 M | 30.15 M | |
| 2021 | -52,885,581 | 7.32 M | 56.82 M | 56.58 M | |
| 2020 | -88,682,530 | 15.41 M | 92.81 M | 92.42 M | |
| 2019 | -129,543,919 | 9.36 M | 133.61 M | 133.04 M |